American Society of Hirudotherapy

Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy

Case report published in Journal of Clinical Microbiology (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportSafety & Infection ControlGiltner CL, Bobenchik AM, Uslan DZ, Deville JG, Humphries RM · Journal of clinical microbiology, 2013

Abstract

We report a case of surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila following leech therapy. Antimicrobial and genetic analyses of leech and patient isolates demonstrated that the resistant isolates originated from the leech gut microbiota. These data suggest that ciprofloxacin monotherapy as a prophylaxis regimen prior to leech therapy may not be effective in preventing infection.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAeromonas hydrophilaAnimalsAnti-Bacterial AgentsCellulitisChildCiprofloxacinDrug Resistance, BacterialFemaleGastrointestinal TractGram-Negative Bacterial InfectionsHirudo medicinalisHumansLeechingSurgical Wound Infection

Summary

A surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila developed following leech therapy. Antimicrobial and genetic analyses of leech and patient isolates showed that the resistant strain originated from the leech's gut microbiota, suggesting ciprofloxacin monotherapy prophylaxis may not prevent infection.

Why This Matters for Hirudotherapy

This case report describes a surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila following leech therapy. Antimicrobial and genetic analyses of both leech and patient isolates demonstrated that the resistant isolates originated from the leech gut microbiota. The authors suggest that ciprofloxacin monotherapy as a prophylaxis regimen prior to leech therapy may not be effective in preventing infection. This finding is relevant to hirudotherapy practice, as it provides microbiological and genetic evidence directly linking a drug-resistant pathogen to the leech gut. However, the evidence is limited to a single case report, and no data on the prevalence of ciprofloxacin-resistant A. hydrophila in leech populations or the comparative efficacy of alternative prophylactic regimens are presented.

Citation

Reference (Vancouver style)

Giltner CL, Bobenchik AM, Uslan DZ, Deville JG, Humphries RM. Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy. J Clin Microbiol. 2013;51(4):1324-1326. doi:10.1128/JCM.03217-12. PMID: 23363826

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 26, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.